HC Wainwright reissued their buy rating on shares of Beyondspring (NASDAQ:BYSI) in a report released on Wednesday morning, Briefing.com Automated Import reports. HC Wainwright currently has a $60.00 target price on the stock.
Separately, Maxim Group reaffirmed a buy rating and set a $58.00 target price on shares of Brinker International in a report on Tuesday, April 30th.
Beyondspring stock opened at $20.70 on Wednesday. The firm’s fifty day moving average is $19.20. Beyondspring has a fifty-two week low of $13.06 and a fifty-two week high of $26.98.
BeyondSpring Inc, a clinical stage biopharmaceutical company, focuses on the development of cancer therapies. The company is advancing its lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia; a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced non-small cell lung cancer; and Phase 1/2 clinical trials with the immuno-oncology agent nivolumab.
Featured Article: Asset Allocation Models, Which is Right For You?
Receive News & Ratings for Beyondspring Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beyondspring and related companies with MarketBeat.com's FREE daily email newsletter.